US6083903A
(en)
*
|
1994-10-28 |
2000-07-04 |
Leukosite, Inc. |
Boronic ester and acid compounds, synthesis and uses
|
US6838477B2
(en)
*
|
1995-04-12 |
2005-01-04 |
President And Fellows Of Harvard College |
Lactacystin analogs
|
FR2758329B1
(fr)
*
|
1997-01-16 |
1999-02-12 |
Synthelabo |
Derives d'imidazole-4-butane boronique, leur preparation et leur utilisation en therapeutique
|
CN1159061C
(zh)
*
|
1997-02-15 |
2004-07-28 |
千年药物公司 |
通过nf-kappab的抑制治疗梗塞
|
US6221888B1
(en)
*
|
1997-05-29 |
2001-04-24 |
Merck & Co., Inc. |
Sulfonamides as cell adhesion inhibitors
|
JP2001517631A
(ja)
*
|
1997-09-25 |
2001-10-09 |
ミレニアム・ファーマシューティカルズ・インコーポレイテッド |
炎症疾患および自己免疫疾患を治療するためのプロテアソーム阻害剤、ユビキチン経路阻害剤、またはユビキチンプロテアソーム経路を介したNF−κBの活性化に干渉する剤
|
TR200000815T2
(tr)
*
|
1997-09-29 |
2000-12-21 |
Point Therapeutics Inc. |
In vitro hematopoietik hücrelerin stimulasyonu.
|
US6831057B2
(en)
*
|
1997-10-28 |
2004-12-14 |
The University Of North Carolina At Chapel Hill |
Use of NF-κB inhibition in combination therapy for cancer
|
CA2219867A1
(en)
*
|
1997-10-31 |
1999-04-30 |
Jiangping Wu |
The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
|
DE19802450A1
(de)
*
|
1998-01-23 |
1999-07-29 |
Hoechst Marion Roussel De Gmbh |
Ustilipide, Verfahren zu deren Herstellung sowie deren Verwendung
|
US6075150A
(en)
|
1998-01-26 |
2000-06-13 |
Cv Therapeutics, Inc. |
α-ketoamide inhibitors of 20S proteasome
|
US6617171B2
(en)
*
|
1998-02-27 |
2003-09-09 |
The General Hospital Corporation |
Methods for diagnosing and treating autoimmune disease
|
FR2779653B1
(fr)
*
|
1998-06-11 |
2002-12-20 |
Inst Nat Sante Rech Med |
Utilisation de composes modulateurs du proteasome en therapie
|
US6462019B1
(en)
|
1998-07-10 |
2002-10-08 |
Osteoscreen, Inc. |
Inhibitors of proteasomal activity and production for stimulating bone growth
|
US6902721B1
(en)
|
1998-07-10 |
2005-06-07 |
Osteoscreen, Inc. |
Inhibitors of proteasomal activity for stimulating bone growth
|
US6838436B1
(en)
*
|
1998-07-10 |
2005-01-04 |
Osteoscreen Inc. |
Inhibitors of proteasomal activity for stimulating bone growth
|
US6979697B1
(en)
*
|
1998-08-21 |
2005-12-27 |
Point Therapeutics, Inc. |
Regulation of substrate activity
|
EP0982317A1
(de)
*
|
1998-08-26 |
2000-03-01 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Bivalente Proteasome Inhibitore
|
NZ511197A
(en)
*
|
1998-10-20 |
2003-08-29 |
Millenium Pharmaceuticals Inc |
Method for monitoring proteasome inhibitor drug action
|
US6492333B1
(en)
|
1999-04-09 |
2002-12-10 |
Osteoscreen, Inc. |
Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors
|
US6890904B1
(en)
*
|
1999-05-25 |
2005-05-10 |
Point Therapeutics, Inc. |
Anti-tumor agents
|
US6649593B1
(en)
*
|
1999-10-13 |
2003-11-18 |
Tularik Inc. |
Modulators of SREBP processing
|
US20040039129A1
(en)
*
|
2000-08-16 |
2004-02-26 |
Hall Dennis G. |
Non-pressurized methods for the preparation of conjugrated solid supports for boronic acids
|
US6919382B2
(en)
|
2000-08-31 |
2005-07-19 |
The Governors Of The University Of Alberta |
Preparation and uses of conjugated solid supports for boronic acids
|
PT1326632E
(pt)
*
|
2000-10-12 |
2007-01-31 |
Viromics Gmbh |
Tratamento para o tratamento de infecções por vírus da hepatite
|
DK2251344T3
(en)
*
|
2001-01-25 |
2016-05-09 |
Us Of America Represented By The Secretary Dept Of Health And Human Services |
Formulation of boronic acid
|
US7112588B2
(en)
*
|
2001-05-21 |
2006-09-26 |
Alcon, Inc. |
Use of proteasome inhibitors to treat dry eye disorders
|
CA2447909C
(en)
|
2001-05-21 |
2011-04-05 |
Alcon, Inc. |
Use of proteasome inhibitors to treat dry eye disorders
|
DE60209227T2
(de)
*
|
2001-05-30 |
2006-08-17 |
Novartis Ag |
2-((n-(2-amino-3-(heteroaryl- oder -aryl)propionyl)aminoacyl)amino)-alkylboronsäurederivate
|
WO2003033507A1
(fr)
*
|
2001-10-12 |
2003-04-24 |
Kyorin Pharmaceutical Co., Ltd. |
Derives d'acide benzylmalonique et inhibiteurs de proteasomes les contenant
|
JPWO2003033506A1
(ja)
*
|
2001-10-12 |
2005-02-03 |
杏林製薬株式会社 |
アミノボラン酸誘導体およびそれを含有するプロテアソーム阻害薬
|
JP4412586B2
(ja)
*
|
2002-01-08 |
2010-02-10 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
エポネマイシンおよびエポキソマイシン類似物およびそれらの用途
|
WO2003077928A1
(en)
*
|
2002-03-12 |
2003-09-25 |
Ariad Pharmaceuticals, Inc. |
Peptide analogues and uses thereof
|
OA12789A
(en)
|
2002-03-13 |
2006-07-10 |
Janssen Pharmaceutica Nv |
Carbonylamino-derivatives as novel inhibitors of histone deacetylase.
|
EP1485099B1
(de)
*
|
2002-03-13 |
2010-07-07 |
Janssen Pharmaceutica N.V. |
Histone-deacetylase-inhibitoren
|
US7592450B2
(en)
*
|
2002-03-13 |
2009-09-22 |
Janssen Pharmaceutica N.V. |
Piperazinyl-, piperidinyl- and morpholinyl-derivatives as inhibitors of histone deacetylase
|
PL214279B1
(pl)
|
2002-03-13 |
2013-07-31 |
Janssen Pharmaceutica Nv |
Pochodna sulfonyloaminowa, sposób jej wytwarzania i zastosowanie oraz kompozycja farmaceutyczna i sposób jej wytwarzania
|
US20050203029A1
(en)
*
|
2002-04-05 |
2005-09-15 |
Ulrich Schubert |
Agents for treating <I>flaviviridae</I>infections
|
WO2003106384A2
(en)
*
|
2002-06-01 |
2003-12-24 |
Johns Hopkins University |
Novel boronic chalcone derivatives and uses thereof
|
AU2003248921A1
(en)
*
|
2002-07-09 |
2004-01-23 |
Point Therapeutics, Inc. |
Boroproline compound combination therapy
|
US20060240011A1
(en)
*
|
2002-08-14 |
2006-10-26 |
Delphine Boulanger |
Use of nf-kappa b inhibitors for the treatment of mastitis
|
US20050176651A1
(en)
*
|
2002-09-09 |
2005-08-11 |
Trigen Limited |
Peptide boronic acids useful in making salts thereof
|
US20060084592A1
(en)
*
|
2002-09-09 |
2006-04-20 |
Trigen Limited |
Peptide boronic acid inhibitors
|
US20050282757A1
(en)
*
|
2002-09-09 |
2005-12-22 |
Trigen Limited |
Peptide boronic acid compounds useful in anticoagulation
|
US7371729B2
(en)
*
|
2002-09-09 |
2008-05-13 |
Trigen Limited |
Boronic acid salts useful in parenteral formulations
|
US20050119226A1
(en)
*
|
2003-09-09 |
2005-06-02 |
Trigen Limited |
Methods for synthesizing organoboronic compounds and products thereof
|
EP1695711A3
(de)
*
|
2002-09-09 |
2008-01-02 |
Trigen Limited |
Parenterale Formulierungen für die selektive Thrombininhibierung enthaltend Borsäuresalze
|
CA2497977A1
(en)
*
|
2002-09-20 |
2004-04-01 |
Alcon, Inc. |
Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
|
MXPA05005923A
(es)
|
2002-12-06 |
2005-09-21 |
Millennium Pharm Inc |
Metodos para la identificacion, valoracion y tratamiento de pacientes con terapia para la inhibicion de la proteasoma.
|
CN100341880C
(zh)
*
|
2003-02-13 |
2007-10-10 |
上海仁虎制药股份有限公司 |
新型硼酸或硼酸酯类化合物、制备方法及在药学上的应用
|
WO2005007211A2
(en)
*
|
2003-07-03 |
2005-01-27 |
Medtronic Vascular Inc. |
Medical devices with proteasome inhibitors for the treatment of restenosis
|
US7223745B2
(en)
*
|
2003-08-14 |
2007-05-29 |
Cephalon, Inc. |
Proteasome inhibitors and methods of using the same
|
US7576206B2
(en)
*
|
2003-08-14 |
2009-08-18 |
Cephalon, Inc. |
Proteasome inhibitors and methods of using the same
|
CA2542886A1
(en)
|
2003-11-05 |
2005-05-19 |
Neelima M. Bhat |
Enhanced b cell cytotoxicity of cdim binding antibody
|
US20060052390A1
(en)
*
|
2003-12-24 |
2006-03-09 |
Scios, Inc. |
Treatment of multiple myeloma by p38 MAP kinase and proteasome inhibition
|
US20050203027A1
(en)
*
|
2004-02-23 |
2005-09-15 |
Trustees Of Tufts College |
Inhibitors of dipeptidylpeptidase IV
|
GB0405272D0
(en)
*
|
2004-03-09 |
2004-04-21 |
Trigen Ltd |
Compounds
|
US7371875B2
(en)
*
|
2004-03-12 |
2008-05-13 |
Miikana Therapeutics, Inc. |
Cytotoxic agents and methods of use
|
RS62738B1
(sr)
*
|
2004-03-30 |
2022-01-31 |
Millennium Pharm Inc |
Sinteza jedinjenja estra organoborne kiseline i organoborne kiseline
|
AU2016202747B2
(en)
*
|
2004-03-30 |
2017-11-23 |
Millennium Pharmaceuticals, Inc. |
Synthesis of boronic ester and acid compounds
|
US8198270B2
(en)
|
2004-04-15 |
2012-06-12 |
Onyx Therapeutics, Inc. |
Compounds for proteasome enzyme inhibition
|
JP5616569B2
(ja)
|
2004-04-15 |
2014-10-29 |
オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. |
酵素阻害のための化合物
|
ES2510840T3
(es)
|
2004-05-10 |
2014-10-21 |
Onyx Therapeutics, Inc. |
Compuestos para la inhibición enzimática del proteosoma
|
WO2006002422A2
(en)
|
2004-06-24 |
2006-01-05 |
Novartis Vaccines And Diagnostics Inc. |
Compounds for immunopotentiation
|
US7842707B2
(en)
|
2004-07-23 |
2010-11-30 |
Nuada, Llc |
Peptidase inhibitors
|
PL1781639T3
(pl)
|
2004-07-28 |
2012-07-31 |
Janssen Pharmaceutica Nv |
Podstawione pochodne indolilo-alkiloaminowe jako nowe inhibitory deacetylazy histonowej
|
AU2005295183A1
(en)
|
2004-10-20 |
2006-04-27 |
CAOnyx Therapeutics, Inc. |
Labeled compounds for proteasome inhibition
|
BRPI0517057A
(pt)
|
2004-11-05 |
2008-09-30 |
Palingen Inc |
composição para induzir ferimento de membrana celular; composição para aumentar o ferimento da membrana celular em uma célula linfóide; composição para permeabilizar uma célula; composição para induzir ferimento da membrana celular em células b; composição para aumentar o ferimento da membrana celular induzido por um anticorpo de ferimento de membrana celular; método de tratamento de um mamìfero que sofre de uma condição distinta por uma hiperproliferação de células; método para matar uma célula cancerosa; método para induzir ferimento de membrana celular em uma célula linfóide em um paciente humano; método para induzir ferimento da membrana celular; método para permeabilizar uma célula; método de purgar a medula óssea de células b malignas de um paciente com esta necessidade; estojo para determinar o limite da dose para um agente polivalente que induz o ferimento da membrana celular em um mamìfero; estojo para determinar o limite da dose para um anticorpo de ferimento de membrana celular em um mamìfero; uso de um agente polivalente de ferimento de membrana celular; e uso de um anticorpo de ferimento de membrana celular
|
TW200618820A
(en)
*
|
2004-11-05 |
2006-06-16 |
Alza Corp |
Liposome formulations of boronic acid compounds
|
US8017395B2
(en)
|
2004-12-17 |
2011-09-13 |
Lifescan, Inc. |
Seeding cells on porous supports
|
US20070098685A1
(en)
*
|
2005-01-19 |
2007-05-03 |
Brand Stephen J |
Methods and kits to treat chronic inflammatory immune diseases by administering a proteasome inhibitor and an interleukin 2 receptor agonist
|
BRPI0606455A
(pt)
|
2005-01-21 |
2008-03-11 |
Astex Therapeutics Ltd |
compostos farmacêuticos
|
US20090018146A1
(en)
*
|
2005-01-27 |
2009-01-15 |
Research Development Corporation |
Combination Therapy with Triterpenoid Compounds and Proteasome Inhibitors
|
US7468383B2
(en)
*
|
2005-02-11 |
2008-12-23 |
Cephalon, Inc. |
Proteasome inhibitors and methods of using the same
|
ES2872962T3
(es)
|
2005-02-16 |
2021-11-03 |
Anacor Pharmaceuticals Inc |
Boronoftalidas para uso terapéutico
|
EP1863513A2
(de)
*
|
2005-03-11 |
2007-12-12 |
The University of North Carolina at Chapel Hill |
Potente und spezifische immunproteasomhemmer
|
WO2006119032A1
(en)
*
|
2005-04-29 |
2006-11-09 |
Kosan Biosciences Incorporated |
Method of treating multiple myeloma using 17-aag or 17-ag or a prodrug of either in combination with a proteasome inhibitor
|
JP5055268B2
(ja)
|
2005-05-18 |
2012-10-24 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
ヒストンデアセチラーゼの新規な阻害剤としての置換されたアミノプロペニルピペリジンまたはモルホリン誘導体
|
AU2006202209B2
(en)
*
|
2005-05-27 |
2011-04-14 |
Lifescan, Inc. |
Amniotic fluid derived cells
|
PL1888123T3
(pl)
*
|
2005-06-08 |
2013-06-28 |
Janssen Biotech Inc |
Terapia komórkowa chorób degeneracyjnych oka
|
EP1912664A2
(de)
*
|
2005-07-06 |
2008-04-23 |
Biodevelops Pharma Entwicklung GmbH |
Verwendung einer verbindung zur verstärkung der expression von membranproteinen auf der zelloberfläche
|
US7531517B2
(en)
|
2005-08-10 |
2009-05-12 |
4Sc Ag |
Inhibitors of cancer cell, T-cell and keratinocyte proliferation
|
EP1752467A1
(de)
|
2005-08-10 |
2007-02-14 |
4Sc Ag |
Krebszellen-, t-Zellen- und Keratinocyte-Proliferation-Inhibitoren
|
US20070059382A1
(en)
*
|
2005-09-09 |
2007-03-15 |
Board Of Regents, Univ. And Comm. College System Of Nevada... |
Medical treatment of breast cancer with boric acid materials
|
HUE034863T2
(en)
*
|
2005-11-09 |
2018-03-28 |
Onyx Therapeutics Inc |
Compound for inhibiting enzyme
|
WO2007067752A2
(en)
*
|
2005-12-08 |
2007-06-14 |
Cytokinetics, Inc. |
Certain compositions and methods of treatment
|
CN106008571A
(zh)
|
2005-12-30 |
2016-10-12 |
安纳考尔医药公司 |
含硼的小分子
|
US8101616B2
(en)
*
|
2006-01-19 |
2012-01-24 |
Janssen Pharmaceutica N.V. |
Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
|
CN101370803B
(zh)
*
|
2006-01-19 |
2012-12-12 |
詹森药业有限公司 |
作为组蛋白脱乙酰酶抑制剂的取代的吲哚基-烷基-氨基衍生物
|
PL1981874T3
(pl)
*
|
2006-01-19 |
2009-10-30 |
Janssen Pharmaceutica Nv |
Pochodne aminofenylowe jako nowe inhibitory deacetylazy histonowej
|
JP5247470B2
(ja)
|
2006-01-19 |
2013-07-24 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
ヒストンデアセチラーゼのインヒビターとしてのピリジン及びピリミジン誘導体
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
PE20070978A1
(es)
*
|
2006-02-14 |
2007-11-15 |
Novartis Ag |
COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
|
KR101622870B1
(ko)
|
2006-02-16 |
2016-05-19 |
아나코르 파마슈티칼스 인코포레이티드 |
항염증제로서 보론함유 소분자
|
AR060358A1
(es)
*
|
2006-04-06 |
2008-06-11 |
Novartis Vaccines & Diagnostic |
Quinazolinas para la inhibicion de pdk 1
|
US8741643B2
(en)
*
|
2006-04-28 |
2014-06-03 |
Lifescan, Inc. |
Differentiation of pluripotent stem cells to definitive endoderm lineage
|
DE102006026464A1
(de)
|
2006-06-01 |
2007-12-06 |
Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma |
Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
|
WO2007143600A2
(en)
*
|
2006-06-05 |
2007-12-13 |
Incyte Corporation |
Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
|
NZ603303A
(en)
|
2006-06-19 |
2014-05-30 |
Onyx Therapeutics Inc |
Peptide epoxyketones for proteasome inhibition
|
EA020276B1
(ru)
*
|
2006-09-15 |
2014-10-30 |
Янссен Фармацевтика Нв |
Ингибиторы гистоновых дезацетилаз с сочетанной активностью в отношении гистоновых дезацетилаз класса i и класса ii в комбинации с ингибиторами протеасом
|
CA2662432A1
(en)
*
|
2006-09-15 |
2008-03-20 |
Janssen Pharmaceutica Nv |
Combinations of class-i specific histone deacetylase inhibitors with proteasome inhibitors
|
US8883790B2
(en)
|
2006-10-12 |
2014-11-11 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
US8916552B2
(en)
|
2006-10-12 |
2014-12-23 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
AU2007221966A1
(en)
*
|
2006-12-08 |
2008-06-26 |
Centenary Institute Of Cancer Medicine And Cell Biology |
Assay for response to proteasome inhibitors
|
JO3396B1
(ar)
|
2007-06-20 |
2019-10-20 |
Anacor Pharmaceuticals Inc |
جزيئات صغيرة تحتوي على البورون
|
US9080145B2
(en)
|
2007-07-01 |
2015-07-14 |
Lifescan Corporation |
Single pluripotent stem cell culture
|
WO2009018453A1
(en)
|
2007-07-31 |
2009-02-05 |
Lifescan, Inc. |
Differentiation of human embryonic stem cells
|
PE20090510A1
(es)
|
2007-08-03 |
2009-05-22 |
Summit Corp Plc |
Combinaciones de drogas para el tratamiento de la distrofia muscular de duchenne
|
GB0715087D0
(en)
|
2007-08-03 |
2007-09-12 |
Summit Corp Plc |
Drug combinations for the treatment of duchenne muscular dystrophy
|
EA034601B1
(ru)
*
|
2007-08-06 |
2020-02-25 |
Милленниум Фармасьютикалз, Инк. |
Способ получения бороновых кислот
|
US7442830B1
(en)
|
2007-08-06 |
2008-10-28 |
Millenium Pharmaceuticals, Inc. |
Proteasome inhibitors
|
AU2016253697A1
(en)
*
|
2007-08-06 |
2016-11-24 |
Millennium Pharmaceuticals, Inc. |
Proteasome inhibitors
|
UA97536C2
(en)
*
|
2007-08-06 |
2012-02-27 |
Милленниум Фармасьютикалз, Инк. |
Proteasome inhibitors
|
BRPI0816807A2
(pt)
*
|
2007-09-12 |
2017-05-16 |
Dr Reddy's Laboratories Inc |
bortezomib e processo para a produção do mesmo
|
US20090076031A1
(en)
*
|
2007-09-17 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched bortezomib
|
WO2009045497A1
(en)
|
2007-10-04 |
2009-04-09 |
Proteolix, Inc. |
Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
|
US7838673B2
(en)
*
|
2007-10-16 |
2010-11-23 |
Millennium Pharmaceuticals, Inc. |
Proteasome inhibitors
|
US20090110688A1
(en)
*
|
2007-10-24 |
2009-04-30 |
Georg Fertig |
Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
|
CN101878298B
(zh)
*
|
2007-11-27 |
2017-08-15 |
生命扫描有限公司 |
人胚胎干细胞的分化
|
CN101220048B
(zh)
*
|
2007-12-14 |
2012-08-15 |
江苏先声药物研究有限公司 |
ZnCl2催化下的蒎烷二醇酯的制备方法
|
CN101952282A
(zh)
|
2007-12-20 |
2011-01-19 |
诺瓦提斯公司 |
用作pi 3激酶抑制剂的噻唑衍生物
|
KR101731474B1
(ko)
|
2008-02-21 |
2017-05-11 |
얀센 바이오테크 인코포레이티드 |
세포 부착, 배양 및 탈리를 위한 방법, 표면 개질 플레이트 및 조성물
|
MX2010009765A
(es)
|
2008-03-06 |
2013-07-12 |
Anacor Pharmaceuticals Inc |
Moleculas pequeñas que contienen boro como agentes anti-inflamatorios.
|
EP2285384A4
(de)
*
|
2008-05-12 |
2012-04-25 |
Anacor Pharmaceuticals Inc |
Borhaltige kleine moleküle
|
PT2730581T
(pt)
*
|
2008-06-17 |
2016-08-17 |
Millennium Pharm Inc |
Compostos de ésteres de boronato e suas composições farmacêuticas
|
KR101829310B1
(ko)
|
2008-06-30 |
2018-02-14 |
얀센 바이오테크 인코포레이티드 |
만능 줄기 세포의 분화
|
CN101638414B
(zh)
*
|
2008-07-30 |
2014-01-08 |
江苏先声药物研究有限公司 |
肽硼酸及其酯类化合物、制备方法及其用途
|
US20100028307A1
(en)
*
|
2008-07-31 |
2010-02-04 |
O'neil John J |
Pluripotent stem cell differentiation
|
WO2010027975A1
(en)
*
|
2008-09-04 |
2010-03-11 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules
|
WO2010028005A1
(en)
|
2008-09-04 |
2010-03-11 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules
|
AR075090A1
(es)
|
2008-09-29 |
2011-03-09 |
Millennium Pharm Inc |
Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
|
WO2010045503A1
(en)
*
|
2008-10-15 |
2010-04-22 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules as anti-protozoal agents
|
EA035100B1
(ru)
|
2008-10-21 |
2020-04-28 |
Оникс Терапьютикс, Инк. |
Комбинированная терапия с применением пептид эпоксикетонов
|
MX349178B
(es)
|
2008-10-31 |
2017-07-17 |
Centocor Ortho Biotech Inc |
Diferenciación de células madre embrionarias humanas al linaje endocrino pancreático.
|
ES2634445T3
(es)
|
2008-10-31 |
2017-09-27 |
Janssen Biotech, Inc. |
Diferenciación de las células madre embrionarias humanas con el linaje endocrino pancreático
|
JP5719305B2
(ja)
*
|
2008-11-20 |
2015-05-13 |
ヤンセン バイオテツク,インコーポレーテツド |
平面支持体上での細胞付着及び培養のための方法及び組成物
|
MX356756B
(es)
|
2008-11-20 |
2018-06-11 |
Centocor Ortho Biotech Inc |
Células madre pluripotentes en microportadores.
|
CN101747354B
(zh)
*
|
2008-12-04 |
2014-08-13 |
江苏先声药物研究有限公司 |
一类β氨基酸组成的二肽硼酸及其酯类化合物、制备方法及其用途
|
PE20120052A1
(es)
*
|
2008-12-17 |
2012-02-13 |
Anacor Pharmaceuticals Inc |
Polimorfos de (s)-3-amino-metil-7-(3-hidroxi-propoxi)-3h-benzo-[c][1,2]-oxaborol-1-ol
|
CA2748921A1
(en)
|
2009-01-09 |
2010-08-12 |
Sun Pharma Advanced Research Company Limited |
Bortezumib containing pharmaceutical composition
|
EP3021120A1
(de)
|
2009-02-20 |
2016-05-18 |
Michael P. Lisanti |
Verfahren zur diagnose oder prognose eines neoplasmas einschliesslich der bestimmung des expressionsgrads eines proteins in stromazellen neben dem neoplasma
|
EP2405916B1
(de)
|
2009-03-12 |
2018-02-07 |
Genentech, Inc. |
Kombination von phosphoinositid 3-kinase inhibitor- verbindungen und chemiotherapeutischen mitteln für die behandlung von blutbildenden bösartigen tumoren
|
TWI504598B
(zh)
|
2009-03-20 |
2015-10-21 |
Onyx Therapeutics Inc |
結晶性三肽環氧酮蛋白酶抑制劑
|
WO2010106135A1
(en)
|
2009-03-20 |
2010-09-23 |
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. |
Combined use for the treatment of ovarian carcinoma
|
HUE027639T2
(en)
*
|
2009-03-24 |
2016-11-28 |
Janssen Pharmaceutica Nv |
Biomarkers for the study of peripheral neuropathy response to treatment with a proteasome inhibitor
|
WO2010114768A1
(en)
*
|
2009-03-30 |
2010-10-07 |
Cerulean Pharma Inc. |
Polymer-epothilone conjugates, particles, compositions, and related methods of use
|
WO2010117668A1
(en)
*
|
2009-03-30 |
2010-10-14 |
Cerulean Pharma Inc. |
Polymer-agent conjugates, particles, compositions, and related methods of use
|
WO2010114770A1
(en)
*
|
2009-03-30 |
2010-10-07 |
Cerulean Pharma Inc. |
Polymer-agent conjugates, particles, compositions, and related methods of use
|
CA2763471A1
(en)
*
|
2009-05-27 |
2010-12-02 |
Cephalon, Inc. |
Combination therapy for the treatment of multiple myeloma
|
EP2270019A1
(de)
|
2009-06-19 |
2011-01-05 |
LEK Pharmaceuticals d.d. |
Neue synthetische Route zur Herstellung von alpha-Aminoborestern
|
CN101928329B
(zh)
*
|
2009-06-19 |
2013-07-17 |
北京大学 |
三肽硼酸(酯)类化合物、其制备方法和应用
|
EP2280016A1
(de)
|
2009-07-27 |
2011-02-02 |
LEK Pharmaceuticals d.d. |
Neue synthetische Route zur Herstellung von Alpha-Aminoborestern über substituierte Alylene
|
CN102803271B
(zh)
|
2009-06-19 |
2016-03-23 |
力奇制药公司 |
氢化卤代烯烃而不脱卤的方法
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
DE102009027754A1
(de)
|
2009-07-15 |
2011-05-05 |
Schubert, Ulrich, Dr. |
Verfahren zur Hemmung der Reifung von dendritischen Zellen
|
RU2540021C2
(ru)
*
|
2009-07-20 |
2015-01-27 |
Янссен Байотек, Инк. |
Дифференцировка эмбриональных стволовых клеток человека
|
CN103952372B
(zh)
|
2009-07-20 |
2016-10-05 |
詹森生物科技公司 |
人胚胎干细胞的分化
|
AU2010276438B2
(en)
|
2009-07-20 |
2015-06-11 |
Janssen Biotech Inc. |
Differentiation of human embryonic stem cells
|
EP2458995A1
(de)
*
|
2009-07-28 |
2012-06-06 |
Anacor Pharmaceuticals, Inc. |
Trisubstituierte borhaltige moleküle
|
WO2011019618A1
(en)
*
|
2009-08-14 |
2011-02-17 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules as antiprotozoal agents
|
WO2011022502A1
(en)
|
2009-08-18 |
2011-02-24 |
Georgetown University |
Boronic acid compositions and methods related to cancer
|
WO2011022337A1
(en)
*
|
2009-08-19 |
2011-02-24 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules as antiprotozoal agents
|
SG10201405568UA
(en)
|
2009-09-08 |
2014-11-27 |
Hoffmann La Roche |
4-substituted pyridin-3-yl-carboxamide compounds and methods of use
|
US20110124597A1
(en)
*
|
2009-09-25 |
2011-05-26 |
Anacor Pharmaceuticals, Inc. |
Boron containing small molecules
|
EP2305285A1
(de)
|
2009-09-29 |
2011-04-06 |
Julius-Maximilians-Universität Würzburg |
Mittel und Verfahren zur Behandlung von ischämischen Erkrankungen
|
HUE032571T2
(en)
|
2009-10-01 |
2017-09-28 |
Janssen Pharmaceutica Nv |
Proteasome inhibitors for cancer treatment
|
US9346834B2
(en)
|
2009-10-20 |
2016-05-24 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules as antiprotozoal agents
|
US8461134B2
(en)
*
|
2009-11-11 |
2013-06-11 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules
|
WO2011060179A1
(en)
|
2009-11-13 |
2011-05-19 |
Onyx Therapeutics, Inc |
Use of peptide epoxyketones for metastasis suppression
|
AU2010341530B2
(en)
*
|
2009-12-22 |
2016-03-10 |
Cephalon, Inc. |
Proteasome inhibitors and processes for their preparation, purification and use
|
WO2011079017A2
(en)
|
2009-12-23 |
2011-06-30 |
Centocor Ortho Biotech Inc. |
Differentiation of human embryonic stem cells
|
WO2011079018A2
(en)
|
2009-12-23 |
2011-06-30 |
Centocor Ortho Biotech Inc. |
Differentiation of human embryonic stem cells
|
US20110178287A1
(en)
|
2010-01-19 |
2011-07-21 |
Cerulean Pharma Inc. |
Cyclodextrin-based polymers for therapeutic delivery
|
WO2011094450A1
(en)
|
2010-01-27 |
2011-08-04 |
Anacor Pharmaceuticals, Inc |
Boron-containing small molecules
|
CN102791851B
(zh)
|
2010-03-01 |
2017-07-14 |
詹森生物科技公司 |
纯化衍生自多能干细胞的细胞的方法
|
CA2791651C
(en)
|
2010-03-01 |
2019-08-20 |
Onyx Therapeutics, Inc. |
Compounds for immunoproteasome inhibition
|
KR101530942B1
(ko)
*
|
2010-03-18 |
2015-06-23 |
이노파르마, 인코포레이티드 |
안정한 보르테조밉 포뮬레이션
|
US8263578B2
(en)
|
2010-03-18 |
2012-09-11 |
Innopharma, Inc. |
Stable bortezomib formulations
|
US8623911B2
(en)
|
2010-03-19 |
2014-01-07 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules as anti-protozoal agent
|
CA2793959C
(en)
|
2010-03-25 |
2019-06-04 |
Oregon Health & Science University |
Cmv glycoproteins and recombinant vectors
|
WO2011123502A1
(en)
|
2010-03-31 |
2011-10-06 |
Millennium Pharmaceuticals, Inc |
Derivatives of 1-amino-2-cyclopropylethylboronic acid
|
AU2013204868B2
(en)
*
|
2010-03-31 |
2016-10-13 |
Millennium Pharmaceuticals, Inc. |
Derivatives of 1-amino-2-cyclopropylethylboronic acid
|
AU2011245630B2
(en)
|
2010-04-07 |
2014-07-03 |
Onyx Therapeutics, Inc. |
Crystalline peptide epoxyketone immunoproteasome inhibitor
|
CN101812026B
(zh)
*
|
2010-04-12 |
2013-08-28 |
亚邦医药股份有限公司 |
一种硼替佐米的合成方法
|
EP2560647B1
(de)
|
2010-04-19 |
2016-04-13 |
Niiki Pharma Inc. |
Kombinationstherapie mit einem proteasomhemmer und einem galliumkomplex
|
WO2011139379A2
(en)
|
2010-05-06 |
2011-11-10 |
Duke University |
A method of treating patients undergoing protein replacement therapy, gene replacement therapy, or other therapeutic modalities
|
EP3498825A1
(de)
|
2010-05-12 |
2019-06-19 |
Janssen Biotech, Inc. |
Differenzierung menschlicher embryonischer stammzellen
|
EP2571525A4
(de)
|
2010-05-18 |
2016-04-27 |
Cerulean Pharma Inc |
Zusammensetzungen und verfahren zur behandlung von autoimmun- und anderen erkrankungen
|
AR082418A1
(es)
|
2010-08-02 |
2012-12-05 |
Novartis Ag |
Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
|
MX355340B
(es)
|
2010-08-31 |
2018-04-16 |
Janssen Biotech Inc |
Diferenciación de células madre embrionarias humanas.
|
SG187947A1
(en)
|
2010-08-31 |
2013-03-28 |
Janssen Biotech Inc |
Differentiation of pluripotent stem cells
|
WO2012030539A2
(en)
|
2010-08-31 |
2012-03-08 |
Janssen Biotech, Inc. |
Differentiation of human embryonic stem cells
|
CN103140228A
(zh)
|
2010-09-07 |
2013-06-05 |
阿纳科制药公司 |
苯并氧杂硼杂环戊二烯衍生物用于治疗细菌感染
|
US9126997B1
(en)
|
2010-09-07 |
2015-09-08 |
Northwestern University |
Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
|
EP2624818B1
(de)
|
2010-10-05 |
2017-04-05 |
Fresenius Kabi USA, LLC |
Mit borsäure stabilisierte bortezomib-formulierungen
|
WO2012048745A1
(en)
|
2010-10-14 |
2012-04-19 |
Synthon Bv |
Process for making bortezomib and intermediates for the process
|
TW201309700A
(zh)
|
2011-01-31 |
2013-03-01 |
Novartis Ag |
新穎雜環衍生物
|
TW201309303A
(zh)
*
|
2011-03-03 |
2013-03-01 |
Cephalon Inc |
用於治療狼瘡的蛋白酶體抑制劑
|
WO2012135528A2
(en)
|
2011-03-29 |
2012-10-04 |
Texas Tech University System |
Galectin-3c combination therapy for human cancer
|
AU2012233171B2
(en)
|
2011-03-31 |
2015-08-20 |
Nanocarrier Co., Ltd. |
Pharmaceutical composition containing block copolymer comprising boronic acid compound
|
AU2012267786B2
(en)
|
2011-06-10 |
2017-08-03 |
Oregon Health & Science University |
CMV glycoproteins and recombinant vectors
|
JP5944986B2
(ja)
*
|
2011-06-22 |
2016-07-05 |
セファロン、インク. |
プロテアソーム阻害剤、ならびにそれらの調製、精製、および使用のためのプロセス
|
US8481655B2
(en)
|
2011-07-27 |
2013-07-09 |
Wacker Chemical Corporation |
Copper complexes of amino-functional organosilicon compounds and their use
|
AU2012294493B2
(en)
|
2011-08-11 |
2017-02-23 |
Janssen Pharmaceutica Nv |
Predictors for cancer treatment
|
WO2013021032A1
(en)
|
2011-08-11 |
2013-02-14 |
Janssen Pharmaceutica Nv |
Histone deacetylase inhibitors in combination with proteasome inhibitors and dexamethasone
|
CA2844086A1
(en)
|
2011-08-19 |
2013-02-28 |
Glaxo Group Limited |
Benzofuran compounds for the treatment of hepatitis c virus infections
|
HRP20221320T1
(hr)
|
2011-08-30 |
2023-01-06 |
Trustees Of Tufts College |
Fap-aktivirani inhibitori proteasoma za liječenje solidnih tumora
|
AU2012216792A1
(en)
|
2011-09-12 |
2013-03-28 |
International Aids Vaccine Initiative |
Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
|
US9402894B2
(en)
|
2011-10-27 |
2016-08-02 |
International Aids Vaccine Initiative |
Viral particles derived from an enveloped virus
|
JP6238900B2
(ja)
|
2011-10-28 |
2017-11-29 |
ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. |
Nae阻害物質に対する応答のバイオマーカー
|
MX340452B
(es)
|
2011-10-28 |
2016-07-08 |
Novartis Ag |
Novedosos derivados de purina y su uso en el tratamiento de enfermedades.
|
EP2776586B1
(de)
|
2011-11-11 |
2018-03-07 |
Millennium Pharmaceuticals, Inc. |
Biomarker der reaktion auf proteasomenhemmer
|
EP2776043B1
(de)
|
2011-11-11 |
2018-02-21 |
Millennium Pharmaceuticals, Inc. |
Biomarker der reaktion auf proteasomenhemmer
|
BR112014011831A2
(pt)
|
2011-11-17 |
2017-05-09 |
Nat Univ Corp Tokyo Medical & Dental Univ |
copolímero em bloco tendo grupo ácido fenilborônico nele introduzido e o uso deste
|
RU2705001C2
(ru)
|
2011-12-22 |
2019-11-01 |
Янссен Байотек, Инк. |
Дифференцировка эмбриональных стволовых клеток человека в одногормональные инсулинположительные клетки
|
US9732101B2
(en)
|
2012-01-18 |
2017-08-15 |
Wisconsin Alumni Research Foundation |
Bioreversible boronates for delivery of molecules into cells
|
US9234048B2
(en)
|
2012-01-18 |
2016-01-12 |
Wisconsin Alumni Research Foundation |
Boronate-mediated delivery of molecules into cells
|
JP6215235B2
(ja)
|
2012-01-24 |
2017-10-18 |
ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. |
癌の治療方法
|
US10085987B2
(en)
|
2012-01-27 |
2018-10-02 |
Thomas Jefferson University |
MCT protein inhibitor-related prognostic and therapeutic methods
|
JP6335796B2
(ja)
|
2012-02-08 |
2018-06-06 |
アイジーエム バイオサイエンシズ インク.Igm Biosciences Inc. |
Cdim結合タンパク質及びその使用
|
AU2013227219A1
(en)
|
2012-03-02 |
2014-10-23 |
Dr. Reddy's Laboratories Limited |
Pharmaceutical compositions comprising boronic acid compounds
|
JP6383292B2
(ja)
|
2012-03-07 |
2018-08-29 |
ヤンセン バイオテツク,インコーポレーテツド |
多能性幹細胞の増殖及び維持のための明確な培地
|
CA2784240C
(en)
|
2012-03-27 |
2014-07-08 |
Innopharma, Inc. |
Stable bortezomib formulations
|
AU2013263043B2
(en)
|
2012-05-16 |
2016-06-16 |
Novartis Ag |
Dosage regimen for a PI-3 kinase inhibitor
|
JP6469003B2
(ja)
|
2012-06-08 |
2019-02-13 |
ヤンセン バイオテツク,インコーポレーテツド |
膵内分泌細胞へのヒト胚性幹細胞の分化
|
EP2679596B1
(de)
|
2012-06-27 |
2017-04-12 |
International Aids Vaccine Initiative |
HIV-1 Env-proteinvariante
|
UY34897A
(es)
|
2012-07-09 |
2014-01-31 |
Onyx Therapeutics Inc |
Profarmacos de inhibidores peptidicos de expoxi cetona proteasa
|
JP2013006855A
(ja)
*
|
2012-09-03 |
2013-01-10 |
Millennium Pharmaceuticals Inc |
プロテアソーム阻害剤
|
US9505787B2
(en)
*
|
2012-09-11 |
2016-11-29 |
Cipla Limited |
Process for preparing of bortezomib
|
JP6486826B2
(ja)
|
2012-10-01 |
2019-03-20 |
ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. |
阻害剤に対する応答を予測するためのバイオマーカーおよび方法、ならびにそれらの使用
|
WO2014072985A1
(en)
|
2012-11-06 |
2014-05-15 |
Natco Pharma Limited |
Novel boronic acid derivatives as anti cancer agents
|
EP2919786A4
(de)
|
2012-11-16 |
2016-06-01 |
Shilpa Medicare Ltd |
Verfahren für kristallines bortezomib
|
WO2014097306A1
(en)
|
2012-12-21 |
2014-06-26 |
Natco Pharma Limited |
Stable and pure polymorphic form of bortezomib
|
BR112015015714A2
(pt)
|
2012-12-31 |
2017-07-11 |
Janssen Biotech Inc |
suspensão e aglomeração de células pluripotentes humanas para diferenciação em célu-las endócrinas pancreáticas
|
ES2837763T3
(es)
|
2012-12-31 |
2021-07-01 |
Janssen Biotech Inc |
Cultivo de células madre embrionarias humanas en la interconexión aire-líquido para la diferenciación en células endocrinas pancreáticas
|
US10370644B2
(en)
|
2012-12-31 |
2019-08-06 |
Janssen Biotech, Inc. |
Method for making human pluripotent suspension cultures and cells derived therefrom
|
ES2942484T3
(es)
|
2012-12-31 |
2023-06-01 |
Janssen Biotech Inc |
Diferenciación de células madre embrionarias humanas en células endocrinas pancreáticas usando reguladores de HB9
|
CA2905751A1
(en)
|
2013-03-13 |
2014-10-09 |
Forma Therapeutics, Inc. |
Novel compounds and compositions for inhibition of fasn
|
EP2986619A1
(de)
|
2013-04-16 |
2016-02-24 |
Cipla Limited |
Verfahren zur herstellung von bortezomib-mannitol-ester
|
WO2014172627A1
(en)
|
2013-04-19 |
2014-10-23 |
Thomas Jefferson University |
Caveolin-1 related methods for treating glioblastoma with temozolomide
|
US9603775B2
(en)
|
2013-04-24 |
2017-03-28 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
WO2015003146A1
(en)
|
2013-07-03 |
2015-01-08 |
Georgetown University |
Boronic acid derivatives of resveratrol for activating deacetylase enzymes
|
EP2848937A1
(de)
|
2013-09-05 |
2015-03-18 |
International Aids Vaccine Initiative |
Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
|
CA2925935A1
(en)
|
2013-10-03 |
2015-04-09 |
Millennium Pharmaceuticals, Inc. |
Method for the prophylaxis or treatment of systemic lupus erythematosus and/or lupus nephritis
|
US10058604B2
(en)
|
2013-10-07 |
2018-08-28 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
CN104586776B
(zh)
*
|
2013-10-30 |
2017-05-17 |
扬子江药业集团上海海尼药业有限公司 |
以硼替佐米为活性成分的制剂及其制备方法
|
WO2015076359A1
(ja)
*
|
2013-11-21 |
2015-05-28 |
国立大学法人北海道大学 |
プロテアソーム阻害性化合物
|
EP3077823B1
(de)
|
2013-12-05 |
2019-09-04 |
The Broad Institute, Inc. |
Zusammensetzungen und verfahren zur identifikation und behandlung von kachexie oder prä-kachexie
|
TN2016000179A1
(en)
|
2013-12-06 |
2017-10-06 |
Novartis Ag |
Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor.
|
EP3102585B1
(de)
|
2014-02-03 |
2021-05-19 |
Ohio State Innovation Foundation |
Boronsäureester und pharmazeutische formulierungen daraus
|
EP2910557A1
(de)
*
|
2014-02-20 |
2015-08-26 |
Ikerchem, S.L. |
Enantiomerenreine tetrasubstituierte Pyrrolidine als Gerüste für Proteasomhemmer und medizinische Anwendungen davon
|
EP3141243B1
(de)
|
2014-05-08 |
2020-07-08 |
The University of Tokyo |
Pharmazeutische zusammensetzung
|
CA2949056A1
(en)
|
2014-05-16 |
2015-11-19 |
Janssen Biotech, Inc. |
Use of small molecules to enhance mafa expression in pancreatic endocrine cells
|
US20150335668A1
(en)
|
2014-05-20 |
2015-11-26 |
Millennium Pharmaceuticals, Inc. |
Method for cancer therapy
|
EP4180041A1
(de)
|
2014-08-07 |
2023-05-17 |
Mayo Foundation for Medical Education and Research |
Verbindungen und verfahren zur behandlung von krebs
|
WO2016050356A1
(en)
*
|
2014-10-01 |
2016-04-07 |
Merck Patent Gmbh |
Boronic acid derivatives
|
WO2016110870A1
(en)
|
2015-01-07 |
2016-07-14 |
Emcure Pharmaceuticals Limited |
Pharmaceutical composition of bortezomid
|
MA41505A
(fr)
|
2015-02-11 |
2017-12-19 |
Millennium Pharm Inc |
Nouvelle forme cristalline d'un inhibiteur de protéasome
|
JP2018510859A
(ja)
|
2015-03-17 |
2018-04-19 |
レオン−ナノドラッグズ ゲーエムベーハー |
安定化されたボロン酸化合物を含むナノ粒子
|
US10174292B2
(en)
|
2015-03-20 |
2019-01-08 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
EP3072901A1
(de)
|
2015-03-23 |
2016-09-28 |
International Aids Vaccine Initiative |
Lösliche hiv-1-hüllglykoproteintrimere
|
WO2016184793A1
(en)
|
2015-05-15 |
2016-11-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for treating a patient with vegfr inhibitor-resistant metastatic renal cell carcinoma
|
WO2016205790A2
(en)
|
2015-06-19 |
2016-12-22 |
Hanlin Scientific, Inc. |
Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis
|
EP3120837A1
(de)
|
2015-07-22 |
2017-01-25 |
Stada Arzneimittel Ag |
Verfahren zur herstellung einer bortezomibester-lösung
|
CN106478700B
(zh)
*
|
2015-08-26 |
2020-12-29 |
杭州雷索药业有限公司 |
硼基取代的苯胺类蛋白激酶抑制剂
|
CN106588965A
(zh)
*
|
2015-10-15 |
2017-04-26 |
北京大学 |
脲拟肽硼酸化合物及其药物组合物、制备方法和用途
|
MX2018005298A
(es)
|
2015-11-02 |
2018-06-22 |
Novartis Ag |
Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
|
EP3389715A4
(de)
|
2015-12-14 |
2019-06-12 |
David K. Thomas |
Zusammensetzungen und verfahren zur behandlung von kardialer dysfunktion
|
CN107151255A
(zh)
*
|
2016-03-06 |
2017-09-12 |
复旦大学 |
硼酸类化合物及其制备方法和用途
|
CN107151254A
(zh)
*
|
2016-03-06 |
2017-09-12 |
复旦大学 |
一种作为20s蛋白酶体抑制剂的硼酸类化合物及其制备方法
|
MA45479A
(fr)
|
2016-04-14 |
2019-02-20 |
Janssen Biotech Inc |
Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen
|
US11447506B2
(en)
|
2016-05-09 |
2022-09-20 |
Anacor Pharmaceuticals, Inc. |
Crystal forms of crisaborole in free form and preparation method and use thereof
|
CN106008572B
(zh)
*
|
2016-05-23 |
2018-08-17 |
成都千禧莱医药科技有限公司 |
一类二肽硼酸化合物及制备方法和用途
|
JP7164521B2
(ja)
|
2016-06-21 |
2022-11-01 |
オリオン・オフサルモロジー・エルエルシー |
炭素環式プロリンアミド誘導体
|
CA3025253A1
(en)
|
2016-06-21 |
2017-12-28 |
Orion Ophthalmology LLC |
Heterocyclic prolinamide derivatives
|
JP6681284B2
(ja)
*
|
2016-06-23 |
2020-04-15 |
信越化学工業株式会社 |
糖アルコール化合物の金属低減方法
|
JP6223508B2
(ja)
*
|
2016-06-27 |
2017-11-01 |
ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. |
プロテアソーム阻害剤
|
WO2018038687A1
(en)
|
2016-08-22 |
2018-03-01 |
Mustafa Nevzat Ilaç Sanayii A.Ş. |
Pharmaceutical formulations comprising a bortezomib-cyclodextrin complex
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|
WO2018073790A1
(en)
|
2016-10-20 |
2018-04-26 |
Pfizer Inc. |
Therapeutic particles with peptide boronic acid or boronate ester compounds and methods of making and using same
|
US11584733B2
(en)
|
2017-01-09 |
2023-02-21 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
WO2018129533A1
(en)
|
2017-01-09 |
2018-07-12 |
Shuttle Pharmaceuticals, Llc |
Selective histone deacetylase inhibitors for the treatment of human disease
|
KR20190127681A
(ko)
|
2017-02-17 |
2019-11-13 |
프레세니어스 카비 온콜로지 리미티드 |
붕소산 에스테르의 개선된 제조방법
|
US11596629B2
(en)
|
2017-02-28 |
2023-03-07 |
Mayo Foundation For Medical Education And Research |
Compounds and methods for treating cancer
|
CN111601597B
(zh)
|
2017-08-23 |
2023-10-13 |
科智生命科学公司 |
自身免疫性病症的治疗中的免疫蛋白酶体抑制剂和免疫抑制剂
|
JP2020533382A
(ja)
|
2017-09-14 |
2020-11-19 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
癌の組合せ治療
|
JP2018024694A
(ja)
*
|
2017-10-03 |
2018-02-15 |
ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. |
プロテアソーム阻害剤
|
AU2018367515B2
(en)
|
2017-11-16 |
2023-04-27 |
Principia Biopharma Inc. |
Immunoproteasome inhibitors
|
JP7333321B2
(ja)
*
|
2017-11-16 |
2023-08-24 |
プリンシピア バイオファーマ インコーポレイテッド |
免疫プロテアソーム阻害剤
|
US10537585B2
(en)
|
2017-12-18 |
2020-01-21 |
Dexcel Pharma Technologies Ltd. |
Compositions comprising dexamethasone
|
US11407723B2
(en)
|
2018-01-09 |
2022-08-09 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
EP3746065A4
(de)
|
2018-01-29 |
2022-02-16 |
Cognos Therapeutics Inc. |
Intratumorale verabreichung von bortezomib
|
TW202003553A
(zh)
|
2018-03-15 |
2020-01-16 |
美商艾伯維有限公司 |
用於治療癌症之abbv-621與抗癌劑之組合
|
US11243207B2
(en)
|
2018-03-29 |
2022-02-08 |
Mayo Foundation For Medical Education And Research |
Assessing and treating cancer
|
EP3873214A4
(de)
|
2018-10-29 |
2022-07-13 |
Forma Therapeutics, Inc. |
Feste formen von (4-(2-fluor-4-(1-methyl-1h-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanon
|
CN109824756B
(zh)
*
|
2019-03-19 |
2022-03-22 |
山东大学 |
含有4-(苯磺酰基)哌嗪-2-酮的苯丙氨酸衍生物及其制备方法与应用
|
CN114437119A
(zh)
*
|
2020-10-30 |
2022-05-06 |
苏州开拓药业股份有限公司 |
一种c-Myc蛋白抑制剂及其制备方法和用途
|
CN116783212A
(zh)
*
|
2020-12-02 |
2023-09-19 |
霍夫曼技术有限责任公司 |
用于调节非人哺乳动物中的癌症的组合物和方法
|
TW202237143A
(zh)
*
|
2020-12-10 |
2022-10-01 |
南韓商Lg化學股份有限公司 |
酸(Boronic Acid)化合物
|
US11964993B2
(en)
|
2021-07-03 |
2024-04-23 |
Shilpa Pharma Lifesciences Limited |
Crystalline bortezomib process
|
US20230062279A1
(en)
|
2021-08-12 |
2023-03-02 |
Extrovis Ag |
Pharmaceutical compositions of bortezomib
|
CN113957441B
(zh)
*
|
2021-10-29 |
2024-01-02 |
光华科学技术研究院(广东)有限公司 |
蚀刻液及其制备方法和应用
|
WO2023220641A2
(en)
|
2022-05-11 |
2023-11-16 |
Juno Therapeutics, Inc. |
Methods and uses related to t cell therapy and production of same
|
WO2023220655A1
(en)
|
2022-05-11 |
2023-11-16 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|